---
title: "Cytokinetics Appoints Robert E. Landry to Board"
date: "2025-02-11 20:53:46"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioCytokinetics ( (CYTK) ) has issued..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_296599349-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Cytokinetics ( [(CYTK)](https://www.tipranks.com/stocks/cytk) ) has issued an update.

On February 10, 2025, Cytokinetics, Incorporated appointed Robert E. Landry to its Board of Directors as a Class II member, with an initial term until the 2027 annual stockholders meeting. Landry was also appointed to the Audit Committee, and he will participate in the company’s non-employee director compensation arrangements, which include annual retainers and equity grants. This appointment aligns with Cytokinetics’ governance policies, as Landry is considered independent under relevant guidelines and requirements.

**More about Cytokinetics**

Cytokinetics, Incorporated operates in the biopharmaceutical industry, focusing on discovering, developing, and commercializing innovative muscle biology-driven therapeutics. The company primarily targets diseases that impair muscle function, aiming to address unmet medical needs in areas such as heart failure and amyotrophic lateral sclerosis (ALS).

**YTD Price Performance:** -13.73%

**Average Trading Volume:** 1,310,601

**Technical Sentiment Consensus Rating:** Hold

**Current Market Cap:** $5.05B

See more data about CYTK stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/cytk/stock-analysis).

Trending Articles:
------------------

* [Elon Musk’s Brother and Tesla Director Kimbal Sells $28M Worth of Stock](https://www.tipranks.com/news/elon-musks-brother-and-tesla-director-kimbal-sells-28m-worth-of-stock)
* [APLT Lawsuit Alert! Class Action Against Applied Therapeutics, Inc.](https://www.tipranks.com/news/aplt-lawsuit-alert-class-action-against-applied-therapeutics-inc)
* [‘Bullish Confirmation Coming,’ Says Investor About Super Micro Computer Stock](https://www.tipranks.com/news/bullish-confirmation-coming-says-investor-about-super-micro-computer-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/cytokinetics-appoints-robert-e-landry-to-board)
